Ga-68 dolacga PET scan for liver cancer before treatment
Part of Cancer, Digestive system clinical trials.
This study tests whether a special PET scan can give clearer images of liver tumors before you receive radiofrequency ablation (RFA), a procedure that uses heat to destroy cancer cells. It may help doctors plan your treatment more precisely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have very early or early stage liver cancer.
- You have no more than 3 tumors in your liver, and each tumor is 3 cm or smaller (or if you have a single tumor, it is 5 cm or smaller).
- You are able to carry out all your normal daily activities without help (performance status 0).
- Your tumors have not spread to blood vessels or other parts of the body.
- You have not had prior treatment for your liver tumors, such as surgery, alcohol injections, or a liver transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging technique that may help doctors see liver cancer more clearly. It uses a special tracer that targets a protein found on many liver cancer cells. This could help with diagnosis and monitoring.
This trial uses a special PET scan (68Ga-FAPI) to see how well systemic therapy is working in people with advanced liver cancer that can't be removed by surgery. The goal is to find a better way to measure treatment effectiveness.
This study tests a new imaging tracer to better see liver cancer on PET scans, which might help doctors find or monitor tumors more accurately.
This trial tests a special PET scan (18F-FSPG) to help guide therapy for people with liver cancer (HCC) who are planning to receive Y90 radioembolization. The scan may help doctors better plan your treatment.
This trial studies how well a special imaging test (68Ga-FAPI PET/MRI) can detect and evaluate hepatocellular carcinoma (HCC), a type of liver cancer. It may help doctors confirm diagnosis and plan next steps by seeing how the cancer takes up the tracer.
This trial tests whether a new PET imaging agent (GPC3-targeted) can find liver cancer as well as or better than enhanced MRI. It may help diagnose hepatocellular carcinoma (the most common type of liver cancer) more accurately.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.